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The impact of peritoneal dialysis (PD) associated peritonitis on peritoneal membrane
integrity is incompletely understood. Children are particularly suited to address this
question, since they are largely devoid of preexisting tissue damage and life-style
related alterations. Within the International Peritoneal Biobank, 85 standardized parietal
peritoneal tissue samples were obtained from 82 children on neutral pH PD fluids with
low glucose degradation product (GDP) content. 37 patients had a history of peritonitis
and 16 of the 37 had two or more episodes. Time interval between tissue sampling
and the last peritonitis episode was 9 (4, 36) weeks. Tissue specimen underwent
digital imaging and molecular analyses. Patients with and without peritonitis were
on PD for 21.0 (12.0, 36.0) and 12.8 (7.3, 27.0) months (p = 0.053), respectively.
They did not differ in anthropometric or histomorphometric parameters [mesothelial
coverage, submesothelial fibrosis, blood, and lymphatic vascularization, leukocyte,
macrophage and activated fibroblast counts, epithelial-mesenchymal transition (EMT),
podoplanin positivity and vasculopathy]. VEGF and TGF-ß induced pSMAD abundance
were similar. Similar findings were also obtained after matching for age and PD vintage
and a subgroup analysis according to time since last peritonitis (<3, <6, >6 months).
In patients with more than 24 months of PD vintage, submesothelial thickness,
vessel number per mmm section length and ASMA fibroblast positivity were higher
in patients with peritonitis history; only the difference in ASMA positivity persisted in
multivariable analyses. While PD duration and EMT were independently associated with
submesothelial thickness, and glucose exposure and EMT with peritoneal vessel density
in the combined groups, submesothelial thickness was independently associated with
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EMT in the peritonitis free patients, and with duration of PD in patients with previous
peritonitis. This detailed analysis of the peritoneal membrane in pediatric patients on PD
with neutral pH, low GDP fluids, does not support the notion of a consistent long-term
impact of peritonitis episodes on peritoneal membrane ultrastructure, on inflammatory
and fibrotic cell activity and EMT. Peritoneal alterations are mainly driven by PD duration,
dialytic glucose exposure, and associated EMT.
Keywords: peritoneal dialysis, peritonitis, peritoneal membrane, glucose, glucose degradation products, TGF-ß,
VEGF, EMT

of emerging encapsulating peritoneal sclerosis (Braun et al.,
2011) – remained largely unchanged. These findings raised
questions regarding the assumption of significantly improved
biocompatibility as reflected by better preservation of peritoneal
membrane integrity and transport function, with neutral pH, low
GDP fluids (Blake, 2018). They also emphasized the need for an
in-depth analysis of the underlying pathomechanisms, with an
ultimate goal of improving PD efficacy and sustainability.
Peritonitis episodes remain a common complication of
PD (Andreoli et al., 1999; Mehrotra et al., 2016) and have
independently been associated with poorer technique and patient
survival (Davies et al., 1996; Boudville et al., 2012; Ye et al.,
2017). In an early study comprising 233 PD patients on acidic,
high GDP fluids, single peritonitis episodes had no effect on
peritoneal small solute transport and UF, whereas recurrent
peritonitis episodes increased the D/P creatinine and reduced
the UF capacity. Functional changes correlated with the severity
of infection as assessed by the cumulative dialysate leukocyte
count (Davies et al., 1996). A more recent study with the same
fluid type and close monitoring of transport function after the
first peritonitis episode suggested recovery of peritoneal small
solute transport within 2 weeks post peritonitis, but only subtotal
recovery of UF (Ates et al., 2000). In a cohort of 137 patients
treated with both low and high GDP fluids and 92 patients with
a history of a single episode of peritonitis, the latter exhibited
significantly and persistently increased small solute transport,
and decreased large molecule transport and UF rates (van Diepen
et al., 2015); subgroup analyses with regard to the PD fluid type
were not performed.
Data on the impact of peritonitis on peritoneal membrane
ultrastructure are few. In Di Paolo et al. (1986) demonstrated
peritonitis associated degeneration of the mesothelium and
alterations of the connective tissue, which partly resolved within
several months of the peritonitis episode. In rodents, acute
peritonitis induced loss of mesothelial cells, EMT, and fibrosis
(Katz et al., 2012; Balogh et al., 2015). Peritoneal overexpression
of the inflammatory cytokines interleukin 1-beta and TNF-alpha,
which are upregulated earliest in patients with acute peritonitis
(Zemel et al., 1994), induced VEGF and angiogenesis, increased
solute permeability and reduced UF (Margetts et al., 2002). We
now provide a detailed analysis of the impact of peritonitis
episodes on peritoneal membrane integrity, cellular infiltration,
EMT, and key cytokine abundance in children treated with
neutral pH, low GDP peritoneal dialysis solutions. Children
are largely devoid of preexisting comorbidities such as age
and life-style related tissue and vascular alterations, mainly

INTRODUCTION
Peritoneal dialysis (PD) provides a cost effective renal
replacement therapy independent of a vascular access, greater
individual freedom and at least equal patient outcome within
the first years of treatment as compared to hemodialysis
(van de Luijtgaarden et al., 2016). It is the preferred dialysis
modality in young children and is increasingly applied in
adults (Mehrotra et al., 2016). PD fluids, however, expose
the peritoneal membrane to glucose concentrations 10–
50 fold above physiological concentrations and depending
on the manufacturing process, to high amounts of toxic
glucose degradation products (GDP), to lactate and an
acidic pH in single chamber PD solutions. With extended
exposure, the peritoneum undergoes profound transformation,
including progressive mesothelial cell loss, submesothelial
fibrosis, angiogenesis, and vasculopathy. At the time of PD
failure, submesothelial blood and lymphatic vessel number
is increased (Williams et al., 2002; Braun et al., 2011). These
morphological changes result in a gradual increase in small
solute transport rates and loss of ultrafiltration (UF) capacity,
requiring exposure to an additional glucose load, which
within a vicious circle ultimately results in UF and PD failure
(Davies et al., 1998, 2001).
Separation of the glucose from the buffer compound, lactate
or bicarbonate, allowed introduction of neutral pH, low GDP
fluids and raised hope to prevent long term deterioration of
the peritoneal membrane, based on numerous in vitro and
experimental in vivo studies (Mortier et al., 2003, 2004, 2005;
Grossin et al., 2006; Rippe, 2009; Bajo et al., 2011). Clinical
trials revealed higher CA125 effluent concentrations (Haas et al.,
2003; Szeto et al., 2007), a putative marker of mesothelial cell
viability, and lower hyaluronic acid and procollagen peptide
concentrations, suggesting improved peritoneal membrane
integrity (Williams et al., 2004). A recent analysis of the
peritoneal membrane in children at the time of PD catheter
insertion, as well as while on chronic PD with neutral pH,
low GDP PD fluids, however, revealed doubling of peritoneal
microvascularisation and endothelial exchange area within a
few months of PD initiation. These findings independently
predicted small solute transport rates. Submesothelial fibrosis
progressed less fast (Schaefer et al., 2018). These changes were
accompanied by induction of VEGF and TGF-β induced SMAD
phosphorylation, by epithelial-mesenchymal transition (EMT),
and by inflammatory cell invasion (Schaefer et al., 2018).
Lymphatic vessel density and podoplanin positivity – markers
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thickness was measured on H&E and CD31 stained slides on
at least five different points. Vessels were stained by CD31,
lymphatic vessels by D2-40. Quantification was performed by
Microvessel algorithm (Aperio Precision Image Analysis), to
calculate the number of blood vessels; podoplanin positive
lymphatics were subtracted from the CD31 positive vessels
(stains both, blood, and lymphatic vessels). Submesothelial
microvessel number/mm was calculated as absolute number
of vessels in the submesothelial area per 1 mm length of
surface peritoneum. Vasculopathy was quantitated as described
previously (Honda et al., 2008; Schaefer et al., 2018). Endothelial
surface area relative to peritoneal volume was calculated for
the total vessel density, blood vessel density, and lymphatic
vessel density in a following way: the endoluminal perimeter
of CD31/podoplanin stained endothelium ∗ section thickness
∗ number of vessels divided by the analyzed peritoneal area
∗ section thickness (µm2 /µm3 ). ASMA positivity and CD45
lymphocyte and CD68 macrophage infiltration was quantified
in a semi-quantitative way (0–3 score). AFOG stained slides
were evaluated for fibrin deposits. EMT cells were determined
as previously described using calretinin staining (Yanez-Mo
et al., 2003) and findings reconfirmed by cytokeratin and
FSP1 co-staining.

suffer from congenital disorders mostly limited to the kidneys
and urinary tract (Harambat et al., 2012) and therefore are
particularly positioned to facilitate the study of PD treatment and
peritonitis induced changes of the peritoneum.

MATERIALS AND METHODS
Biopsy Sampling
Parietal peritoneal biopsy samples from 25 centers were obtained
within the scope of the International Pediatric Peritoneal
Biobank study. Sampling followed a standardized protocol as
described previously (Schaefer et al., 2016). All samples were
fixed with needles on cork and instantaneously stored in
formalin. After transfer to Heidelberg, parietal tissue samples
were embedded in paraffin and underwent immunostaining
and digital imaging analysis. Case report forms were provided
online via the International Peritoneal Dialysis Network1 or by
mail and entered into the central data base. The protocol was
approved by local ethical boards and performed in accordance
with the local national Medical Association’s professional code
of conduct (Landesärztekammer Baden-Württemberg) and the
declaration of Helsinki. Oral and written consent was obtained
from parents and patients as appropriate. The study was
registered at www.clinicaltrials.gov (NCT01893710). Between
February 2011 and January 2018, 87 parietal peritoneal samples
were obtained from 84 children on neutral pH, low GDP
PD fluid (45 with pH 7.4 bicarbonate fluid, 15 with pH 7.0
lactate fluid, 24 with pH 7.4 lactate/bicarbonate fluid). The
effect of the low GDP PD treatment on peritoneal membrane
integrity and function has been published previously (Schaefer
et al., 2018). This analysis focused on the distinct effects of
peritonitis episodes. Three patients underwent a repeat biopsy,
2 of whom had experienced a single episode of peritonitis
before the first sampling. These biopsies were included in the
present analysis. The median patient age was 5.7 (2.7, 13.5)
years, and PD vintage was 16.9 (7.3, 36.0) months. Daily dialytic
glucose exposure was calculated from the most recent, stable
PD regime. Two patients with candida peritonitis were excluded
from the analysis.

Statistics
Data distribution was assessed graphically and by Shapiro–
Wilk test. Data are presented as median with interquartile
range (IQR). To assess the differences between the groups,
ANOVA or Kruskal–Wallis test were used based on the data
distribution. Because of the low sample size, matching by
the coarsened exact matching method (Blackwell et al., 2009)
was performed for age, PD duration and glucose exposure.
The exposure variable was history of peritonitis. Patients
without peritonitis were matched to patients with any positive
number of previous peritonitis episode. Multivariable linear
regression analyses in a forward entry, starting with a univariate
analyses were performed to test the PD characteristics with the
peritoneal morphology in patients with and without peritonitis;
log transformation was performed in case of unequal data
distribution. Analyses were performed by STATA13 software
(StataCorp, College Station, TX, United States), two-sided
tests were performed.

Immunostaining
All specimens underwent hematoxylin-eosin (H&E) and acid
fuchsin orange (AFOG) staining according to standard protocols.
Immunostaining was performed with the following antibodies:
calretinine, podoplanin (D2-40), CD31, CD45, CD68, ASMA
(alpha smooth muscle actin), FSP-1, and cytokeratin. All
slides were scanned using Nanozoomer Digital pathology
system and analyzed by digital microscopy using Aperio
Image Scope version 11. Mesothelial cells integrity was
assessed on H&E, calretinine, and podoplanin stained slides
and quantified in a semi-quantitative way (0 = no cells
present, 1 = 1–24% of the surface covered, 2 = 25–49%
of the surface covered, 3 = 50% of cells present, 4 = 51–
75%, 5 = 76–95%, 6 = complete coverage). Submesothelial
1

RESULTS
Patient Population
Out of 82 patients included in the analysis, 37 patients had
a history of peritonitis, and 16 out of the 37 had two or
more peritonitis episodes. Time interval between the last
peritonitis episode and tissue sampling was 9 (4, 36) weeks.
The organisms causing peritonitis were Staphylococcus (aureus,
warneri), Enterococcus faecalis, Brevundimonas vesicularis,
Enterobacter (cloacae, asburiae), Haemophilus influenzae,
Klebsiella pneumoniae, Escherichia coli, Streptococcus pyogenes,
and Pseudomonas (stutzeri and aeruginosa). In seven episodes
the dialysate culture remained negative and in three episodes
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TABLE 1 | Patient and PD treatment characteristics and blood biochemistry at time of biopsy.
No peritonitis

Previous peritonitis

p-value

Patients (n)

47

38

Age (years)

6.2 (2.7, 11.8)

5.3 (2.4, 13.5)

48%

44%

0.75

0.8 (0.5, 1.1)

0.8 (0.5, 1.4)

0.57

PD duration (months)

12.8 (7.3, 27.0)

21.0 (12.0, 36.0)

0.053

Glucose exposure (g/m2 /day)

100 (91, 160)

105 (95, 127)

0.75

Urine output (ml/24 h)

800 (213, 1225)

500 (150, 1100)

0.51

Gender (% female)
BSA (m2 )

Anuric (%)
Creatinine (mg/dl)

19
8 (4.2, 11.27)

0.87

39

0.064

5.05 (3.34, 8.61)

0.22

Albumin (g/l)

37 (34, 40)

35 (31, 41)

0.51

BUN (mg/dl)

57 (38, 67)

42 (21, 57)

0.09

Hemoglobin (g/dl)

10.2 (9.4, 11.5)

10.8 (9.5, 11.7)

0.66

Calcium (mmol/l)

2.4 (2.35, 2.5)

2.4 (2.3, 2.5)

0.33

Phosphorus (mmol/l)

1.73 (1.44, 2.05)

1.65 (1.38, 1.93)

0.53

PTH (pmol/l)

18.3 (12.5, 42.9)

21.4 (10.3, 40.5)

0.75

Bicarbonate (mmol/l)

24 (21, 26)

23 (21, 27)

0.96

BSA, Body surface area; BUN, blood urea nitrogen; PTH, Parathyroid hormone.
TABLE 2 | Characteristics and morphological findings of the patients treated with low GDP PD with and without history of peritonitis.
No peritonitis
Tissue samples (n)
Mesothel absent

Previous peritonitis

p-value

47

38

42%

43%

0.87

1 (0, 3)

0.33

Mesothel score (0–6)

1.5 (0, 3.5)

Submesothelial thickness (µm)

352 (264, 475)

419 (264, 550)

0.49

Microvessel density (/mm2 )

184 (112, 325)

169 (102, 251)

0.50

Submesothelial microvessel number (/mm)

60 (33, 138)

80 (30, 115)

0.60

Lymphatic vessel density (/mm2 )

24 (12, 48)

29 (21, 43)

0.49

25%

26%

0.94

Blood cap. vessel density (/mm2 )

176 (74, 270)

143 (66, 266)

0.52

Total endothelial surface area (µm2 /µm3 )

10.0 (7.0, 18.3)

9.6 (5.7, 13.3)

0.35

Lym. endothelial surface area (µm2 /µm3 )

1.9 (0.9, 4.2)

2.0 (1.3, 3.6)

0.75

Blood cap. end. surface area (µm2 /µm3 )

8.1 (5.4, 12.9)

6.8 (2.1, 13.0)

0.25

L/V ratio

0.4 (0.2, 0.5)

0.4 (0.3, 0.5)

0.76

47%

59%

0 (0, 1)

1 (0, 2)

Diffuse podoplanin staining

ASMA positivity (%)
ASMA score (0–3)
CD45 positivity (%)
CD45 score (0–3)

66%

65%

1 (0, 2)

1 (0, 2)

CD68 positivity (%)

60%

CD68 score (0–3)

1 (0, 1.5)

70%
1 (0, 2)

0.27
0.081
0.97
0.075
0.18
0.075

Fibrine positivity (%)

21%

22%

EMT presence

33%

41%

0.93
0.49

EMT (cells/mm2 )∗

30.0 (15.0, 79.6)

18.0 (5.0, 60.3)

0.22

VEGF (% submesothelial area)

33.6 (17.6, 57.0)

32.4 (20.3, 42.9)

0.35

pSMAD (% submesothelial area)

14.2 (5.4, 27.0)

20.6 (8.7, 28.6)

0.19

Cap., capillary; end., endothelial; submes., submesothelial; lym., lymphatic; L/V ratio, lumen diameter/vessel ratio; ASMA, alpha smooth muscle actin; EMT, epithelial to
mesenchymal transition. VEGF, vascular endothelial growth factor. ∗ Only cell scores from EMT positive patients included.

Histological Findings

the organism was not reported. Patient and PD treatment
characteristics are given in Table 1. At the time of biopsy, the
PD vintage was 8 months shorter in the peritonitis free patients,
while dialytic glucose exposure and anthropometric parameters
were similar in both groups.

Frontiers in Physiology | www.frontiersin.org

Despite a longer PD duration, patients with a history of
peritonitis did not differ in any of the histomorphometric
parameters from peritonitis free patients (Table 2). The
extent of mesothelial cell loss, submesothelial fibrosis and
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After matching groups for age, PD duration and
PD related daily glucose exposure and age, all 23
histomorphometric, cellular, and inflammatory parameters
were comparable (Table 3).
To account for potential temporal differences, a subgroup
analysis was performed according to the time since last
peritonitis (<3, <6, >6 months), and again, all findings were
comparable in both groups.
When stratifying patients according to the number of
peritonitis episodes experienced, the mesothelium was
significantly less well preserved in patients with two and
more peritonitis episodes and the L/V ratio (e.g., vasculopathy)
was more severe (Table 4). These patients, however, were on
PD for a longer period of time and the difference did not persist
in multivariable analysis when PD duration was included as an
independent variable (Supplementary Table S2b).
Patients who have been on PD for at least 24 months
and had a history of peritonitis had a higher submesothelial
thickness and a higher number of vessels per mm section

hypervascularization (i.e., blood and lymphatic vessel density
per mm2 peritoneal surface area and per mm submesothelial
tissue section length) were comparable, as were the respective
endothelial surface areas available for peritoneal fluid and
solute transport. Both patients groups had a similar lumen
over vessel ratio. This L/V ratio was lower as previously
reported for children with normal renal function and
children with CKD5 (Schaefer et al., 2018), i.e., the PD
patients exhibited significant peritoneal vasculopathy. The
relative proportion of patients with ASMA positive, activated
submesothelial fibroblasts, CD45 positive leukocytes, and CD68
positive macrophages were comparable, the differences in
respective semiquantitative cell scores did not reach statistical
significance in unadjusted and multivariable adjusted models
(Table 2 and Supplementary Table S1). EMT cells, key
cells in the peritoneal transformation process, and key
cytokines associated with peritoneal angiogenesis, VEGF,
and with fibrosis, TGF-ß induced pSMAD, were not different
in the two groups.

TABLE 3 | Comparisons of age, PD-vintage and dialytic glucose exposure matched low GDP PD patients with and without history of peritonitis.
No peritonitis

Previous peritonitis

p-value

Patients (n)

24

24

Age (years)

4.0 (1.8, 9.4)

3.3 (1.5, 10.1)

46%

58%

0.39

0.6 (0.4, 1.2)

0.6 (0.5, 1.0)

0.88

500 (300, 1100)

0.45

Gender (% female)
BSA (m2 )
Urine output (ml/24 h)
Anuric (%)
PD duration (months)∗
Glucose exposure (g/m2 /day)
Mesothel absent
Mesothel score (0–6)

1050 (400, 1425)

0.71

29

47

0.27

11.3 (8.5, 21.4)

12.0 (8.5, 22.4)

0.66

97 (89, 132)

100 (85, 108)

0.64

46%

38%

0.53

0.5 (0.0, 3.5)

1.0 (0.0, 3.0)

0.91

Submesothelial thickness (µm)

304 (200, 358)

413 (250, 500)

0.24

Microvessel density (/mm2 )

200 (107, 325)

170 (97, 318)

0.82

Submesothelial microvessel number (/mm)

59 (32, 75)

82 (30, 116)

0.21

Lymphatic vessel density (/mm2 )

39 (23, 56)

33 (22, 46)

0.41

Diffuse podoplanin staining

33%

23%

0.42

Blood cap. vessel density (/mm2 )

176 (71, 328)

139 (66, 362)

0.72

Total endothelial surface area (µm2 /µm3 )

10.0 (7.7, 19.0)

10.2 (5.9, 16.4)

0.82

Lym. endothelial surface area (µm2 /µm3 )

3.4 (1.8, 5.7)

2.6 (1.3, 4.4)

0.30

Blood cap. end. surface area (µm2 /µm3 )

8.0 (4.1, 12.8)

6.7 (3.3, 15.7)

0.89

L/V ratio

0.4 (0.2, 0.5)

0.4 (0.3, 0.5)

0.28

54%

58%

0.77

1 (0, 1)

1 (0, 2)

0.55

ASMA positivity (%)
ASMA score (0–3)
CD45 positivity (%)

83%

CD45 score (0–3)

1 (1, 1.5)

CD68 positivity (%)

67%

CD68 score (0–3)

1 (0, 1.5)

71%

0.30

1 (0, 2)

0.89

79%

0.33

2 (1, 2)

0.11
1.00

Fibrine positivity (%)

25%

25%

EMT presence

46%

42%

EMT (cells/mm2 )∗∗

49 (20, 198)

21 (8, 65)

0.77
0.34

VEGF (% submes. area)

32.2 (19.2, 63.1)

35.0 (20.3, 51.1)

0.50

pSMAD (% submes. area)

18.1 (6.2, 29.1)

20.3 (7.3, 26.7)

0.65

Cap., capillary; end., endothelial; submes., submesothelial; lym., lymphatic; L/V ratio, lumen diameter/vessel ratio; ASMA, alpha smooth muscle actin; EMT, epithelial to
mesenchymal transition. VEGF, vascular endothelial growth factor. ∗ At time of biopsy. ∗∗ Only cell scores from EMT positive patients included.

Frontiers in Physiology | www.frontiersin.org

5

April 2019 | Volume 10 | Article 356

Bartosova et al.

Peritonitis and Membrane Transformation

TABLE 4 | Comparisons of PD patients according to the number of previous peritonitis episodes.
No peritonitis
Tissue samples (n)
Age (years)
Gender (% female)
BSA (m2 )

1 peritonitis

≥ 2 peritonitis

47

22

16

6.1 (2.6, 11.3)

6.2 (1.6, 16.4)

6.7 (3.1, 13.2)

46%

55%

0.8 (0.5, 1.1)

PD duration (months)∗

12.4 (7.3, 24.5)

Glucose exposure (g/m2 /day)

99.7 (91.6, 177.6)

0.9 (0.5, 1.5)

p-value

0.96

38%

0.58

0.8 (0.6, 1.1)

0.74

13.8 (9.0, 26.0)

32.9 (21.0, 70.0)

0.018

101.8 (96.3, 117.1)

111.9 (94.8, 153.8)

0.62

39%

27%

71%

0.037

1.5 (0.0, 4.0)

2.0 (0.0, 3.0)

0.0 (0.0, 1.0)

0.045

Submesothelial thickness (µm)

352 (258, 450)

305.3 (267, 500)

510 (300.2, 767.3)

0.21

Microvessel density (/ mm2 )

194 (115, 336)

159 (95, 211)

192 (150, 271)

0.15

Microvessel number (/mm)

61.3 (32.8, 155, 3)

50.4 (27, 82.1)

96.2 (79.9, 179, 4)

0.059

Lymphatic vessel density (/mm2 )

24.4 (12.0, 48.2)

22.7 (18.5, 35.4)

33.3 (28.3, 46.3)

0.44

Mesothel absent
Mesothel score (0–6)

Diffuse podoplanin staining
Blood cap. vessel density (/mm2 )

22%

30%

175.7 (74.1, 269.5)

128.6 (63.2, 190.0)

29%
188.1 (123.9, 406.2)

0.71
0.32

10.1 (7.4, 18.7)

9.0 (5.2, 11.8)

10.2 (8.5, 15.5)

0.17

Lymphatic end. surface area (µm2 /µm3 )

1.9 (0.9, 4.2)

1.7 (1.2, 3.7)

2.5 (1.6, 2.9)

0.94

Blood cap. end. surface area (µm2 /µm3 )

8.1 (5.4, 12.9)

4.6 (2.1, 8.9)

7.7 (4.0, 15.7)

0.20

L/V ratio

0.4 (0.3, 0.5)

0.5 (0.4, 0.5)

0.3 (0.2, 0.4)

0.018

ASMA positivity (%)

48%

59%

53%

0.68

ASMA score (0–3)

0.0 (1.0, 1.0)

1.0 (0.0, 2.0)

1.0 (0.0, 3.0)

0.42

Total end. surface area (µm2 /µm3 )

CD45 positivity (%)

67%

68%

65%

0.97

CD45 score (0–3)

1.0 (0.0, 2.0)

1.5 (1.0, 2.0)

1.0 (0.0, 2.0)

0.76

CD68 positivity (%)

57%

77%

65%

0.25

CD68 score (0–3)

1.0 (0.0, 2.0)

1.5 (1.0, 2.0)

1.0 (0.0, 2.0)

0.15

Fibrine positivity (%)

22%

18%

24%

0.91

EMT presence

33%

41%

41%

0.72

EMT (cells/mm2 )∗∗

35.0 (10.0, 95.0)

23.0 (6.1, 45.3)

15.0 (1.0, 60.3)

0.45

VEGF (% submes. area)

33.6 (17.6, 57.0)

33.3 (20.3, 42.2)

28.7 (21.1, 49.5)

0.64

pSMAD (% submes. area)

15.3 (5.8, 27)

13.6 (6.6, 26.2)

25.8 (12.2, 33.6)

0.068

Cap., capillary; end., endothelial; submes., submesothelial. L/V ratio, lumen diameter/vessel ratio; ASMA, alpha smooth muscle actin; EMT, epithelial to mesenchymal
transition. VEGF, vascular endothelial growth factor. ∗ At time of biopsy. ∗∗ Only cell scores from EMT positive patients included.

length, but did not differ in the vessel density per section
area compared to patients with a similar dialysis vintage and
no history of peritonitis (Table 5). They were also more
likely to have activated ASMA positive submesothelial
fibroblasts compared to peritonitis free patients. In
multivariable analyses, adjusting for PD duration and
glucose exposure, the difference in ASMA positivity remained
significant (p = 0.012).
In multivariable analyses comprised of data from all biopsies
and after adjusting for age, previous peritonitis, dialytic glucose
exposure, PD duration and presence of EMT, submesothelial
thickness was independently associated with PD duration and
the presence of EMT (p = 0.002/0.036). Glucose exposure
independently predicted peritoneal vessel density and EMT
submesothelial microvessel number per mm tissue section
(p = 0.078 and 0.027) (Supplementary Tables S2a–c). In
subgroup analyses, after adjusting for age, glucose exposure, PD
duration and EMT, submesothelial thickness was independently
associated with EMT in peritonitis free patients (p = 0.04),
and with duration of PD in patients with previous peritonitis
(p = 0.01) (Supplementary Tables S2d,e).

Frontiers in Physiology | www.frontiersin.org

DISCUSSION
This is the first detailed analysis of the long term impact of
peritonitis on peritoneal membrane integrity in a substantial
number (n = 82) of pediatric patients on chronic PD. Patients
with and without a history of peritonitis did not differ in any
of the histomorphometric parameters, nor in inflammatory cell
invasion, EMT, or cytokine expression. These findings suggest
that, PD fluid associated toxicity in contrast to peritonitis
episodes drives peritoneal membrane transformation.
Experimental in vivo studies have previously demonstrated
major peritoneal inflammatory and fibrotic changes with
bacterial and LPS induced peritonitis (Hautem et al., 2017).
Repeated peritoneal equilibration tests suggest rapid recovery
of peritoneal solute transport in most patients after a single
episode of peritonitis (Davies et al., 1996; Ates et al., 2000),
but persistent changes with repeated peritonitis episodes (Davies
et al., 1996), ultimately associating with worse technique and
patient outcome (Boudville et al., 2012; Ye et al., 2017).
Most of these data were obtained in patients treated with
acidic, high GDP PD fluids. In a recent RCT, patients
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TABLE 5 | Comparisons low GDP PD patients with and without history of peritonitis, who were on PD for at least 24 months.
No peritonitis
Tissue samples (n)
Age (years)
Gender (% female)
BSA (m2 )
PD duration (months)∗
Glucose exposure (g/m2 /day)
Mesothel absent
Mesothel score (0–6)
Submesothelial thickness (µm)

Previous peritonitis

p-value

14

16

7.4 (4.4, 16.7)

13.2 (6.7, 18.0)

42%

38%

0.82

0.7 (0.6, 1.3)

1.0 (0.8, 1.3)

0.20

37.6 (30.3, 48.0)

52.0 (32.9, 73.0)

0.30

124.4 (64.3, 216.2)

119.8 (111.9, 146.2)

0.82

50%
0 (0, 2)
314 (223.3, 511.0)

0.35

76%

0.32

0 (0, 1.5)

0.42

527 (308.5, 844.0)

0.058

157.4 (97.9, 278.7)

192.4 (149.7, 236.6)

0.96

Submesothelial microvessel number (/mm)

43.4 (26.0, 66.5)

85.9 (53.1, 179.4)

0.014

Lymphatic vessel density (/mm2 )

53.5 (14.5, 59.0)

25.1 (14.9, 39.5)

0.41

25%

41%

0.37

Blood cap. vessel density (/mm2 )

96 (65, 204)

189 (126, 224)

0.57

Total endothelial surface area (µm2 /µm3 )

8.2 (5.5, 15.2)

9.7 (8.5, 11.5)

0.93

Lym. endothelial surface area (µm2 /µm3 )

4.1 (1.1, 5.8)

1.7 (0.9, 2.5)

0.14

Blood cap. end. surface area (µm2 /µm3 )

7.3 (2.3, 9.0)

7.5 (6.8, 10.9)

0.62

L/V ratio

0.5(0.2, 0.5)

0.4 (0.2, 0.5)

0.52

ASMA positivity (%)

33%

71%

0.017

ASMA score (0–3)

0.0 (0.0, 1.5)

2.0 (0.0, 3.0)

0.56

Microvessel density (/mm2 )

Diffuse podplanin staining

CD45 positivty (%)

50%

76%

0.23

CD45 score (0–3)

0.5 (0.0, 1.0)

1.0 (1.0, 2.0)

0.79

CD68 positivity (%)

67%

76%

0.73

CD68 score (0–3)

1.0 (0.0, 1.0)

1.0 (1.0, 2.0)

0.14

Fibrine positivity (%)

8%

18%

0.47

EMT presence

25%

53%

0.13

EMT (cells/mm2 )∗∗

20.0 (5.0, 20.0)

11.3 (3.0, 26.6)

0.92

VEGF (% submes. area)

46.6 (16, 49.7)

28.7 (22.2, 42.9)

0.44

pSMAD (% submes. area)

11.7 (9.2, 18.2)

25.8 (8.5, 33.6)

0.11

Cap., capillary; end., endothelial; lym., lymphatic; submes., submesothelial. L/V ratio, lumen diameter/vessel ratio; ASMA, alpha smooth muscle actin; EMT, epithelial to
mesenchymal transition. VEGF, vascular endothelial growth factor. ∗ At time of biopsy. ∗∗ Only cell scores from EMT positive patients included.

do not support the notion of peritonitis related peritoneal
sequelae. In parietal peritoneal tissue from patients who had
experienced previous peritonitis episodes, we did not observe
any differences in histomorphological features, inflammatory cell
invasion, in VEGF, and in TGF-ß induced pSMAD abundance
and in the degree of EMT, as compared to peritoneal specimens
from peritonitis free patients. EMT cells secrete VEGF and
TGF-ß (Aroeira et al., 2005, 2007) and thus represent key
mediators of the peritoneal transformation process (YanezMo et al., 2003; Lopez-Cabrera, 2014), albeit their origin
is debated (Chen et al., 2014). Matching for age to rule
out preexisting differences in age related peritoneal thickness
and vascularization (Schaefer et al., 2016), as well as for
PD vintage and dialytic glucose exposure, reconfirmed the
findings. Likewise, analyses according to the time interval since
the last peritonitis episode, and the number of peritonitis
episodes did not demonstrate any significant differences. In
the small subgroup of patients with more than 2 years of
PD, peritonitis positive patients exhibited some differences.
The likelihood of activated fibroblast positivity persisted in
multivariable analysis, suggesting that in patients on long
term PD, peritonitis episodes may be associated with some

treated with neutral pH, low GDP PD fluid experienced less
frequent and less severe episodes of peritonitis as compared
to patients treated with high GDP fluids (Johnson et al.,
2012). Albeit, not analyzed in that trial, the suggestion
has been made that the impact of peritonitis episodes on
peritoneal membrane integrity and transport function may
be less pronounced in patients treated with low GDP fluids.
These assumptions, however, could not be reconfirmed in a
recent meta-analysis (Cho et al., 2014). Peritoneal biopsies
taken from 5 patients treated with high GDP fluids during
acute peritonitis and one to 4 months thereafter demonstrated
persistent mesothelial alterations and submesothelial sclerotic
lesions (Di Paolo et al., 1986).
A more recent study comparing peritoneal morphology
of 23 patients on low and 23 patients on high GDP fluid,
suggested better preservation of the mesothelial cell layer and
less submesothelial fibrosis and vasculopathy with low GDP
fluid. These differences, however, were lost when previous
peritonitis episodes were taken into account, suggesting that
potential benefits of the low GDP fluid are superimposed
by untoward peritonitis effects (Del Peso et al., 2016). Our
findings in pediatric patients who used low GDP PD fluids

Frontiers in Physiology | www.frontiersin.org
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activity and EMT. Peritoneal alterations are primarily driven by
PD duration and dialytic glucose exposure.

enhanced peritoneal profibrotic activity, but the statistical power
of this subgroup analysis is limited. In the multivariable analysis
of the entire cohort, peritonitis did not predict any of the key
morphological peritoneal parameters.
In contrast to the minor differences attributable to
peritonitis history, PD duration and dialytic glucose
exposure independently predicted the peritoneal membrane
histomorphology. In multivariable analyses of all patients,
PD duration predicted submesothelial thickness, and glucose
exposure predicted peritoneal vessel density. PD treatment
induced EMT (Aroeira et al., 2007) was associated with
both submesothelial fibrosis and vessel density. History of
peritonitis and the number of previous peritonitis did not predict
key histomorphological outcome parameters. In subgroup
analyses according to peritonitis history, submesothelial
thickening was independently associated with EMT in peritonitis
free patients, and with duration of PD in patients with
previous peritonitis. The independent association of both
submesothelial fibrosis and submesothelial vessel density
with the presence of EMT cells points to the key role of
EMT in the peritoneal transformation process. EMT, in
turn, represents a potential biomarker, and therapeutic target
(Aufricht et al., 2017).
Of note, during the past few decades, prevention and
treatment of peritonitis has increasingly been guided by evidence
based and repeatedly updated international recommendations
(KDQQI guidelines) (Li et al., 2016). Not only has the incidence
of peritonitis declined (Campbell et al., 2015), but peritonitis
episodes are usually recognized early and broad spectrum
antibiotic treatment covering most of the bacteria is initiated
promptly. None of the centers reported unsuccessful treatment
of the peritonitis episodes.
Our study has important limitations. Although this is
the largest study on peritonitis induced changes of the
peritoneal membrane thus far, the number of patients is
not extensive, and thus the sensitivity is low. Moreover, and
despite current recommendations (Mujais et al., 2000; National
Kidney Foundation, 2006), only a minority of the contributing
centers performed PET and therefore the impact of peritonitis
episodes on peritoneal membrane function could not be studied
comprehensively. On the other hand, strength of the study is
the patient population as children are devoid of life style and
aging related preexisting tissue damage and the predominant
underlying diseases of these patients, such as congenital
abnormalities of the kidneys and urinary tract, do not affect
peritoneal integrity. This allows for a more sensitive and specific
analysis. Whether growing children have a greater plasticity and
thus a greater potential to compensate for peritonitis induced
transient peritoneal damage is unknown.
In conclusion, our detailed analysis of the peritoneal
membrane in pediatric patients on maintenance PD with neutral
pH, low GDP fluids, does not support the notion of a consistent
long-term impact of peritonitis episodes on the peritoneal
membrane ultrastructure, on inflammatory and fibrotic cell
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